However, among these small‐molecule drugs, only GNE‐317 has been validated to cross the BBB (Figure 7C).[32] Analysis of the TCGA GBM database suggests that MSN may influence chemoradiotherapy resistance via the PI3K/mTOR signaling pathway (Figure S8A–E, Supporting Information). This evidence concerns the gene MTOR and glioblastoma.